Kestra Medical Technologies, Ltd. (KMTS) News
Track canonical SquawkNews coverage tagged to KMTS, Kestra Medical Technologies, Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 29 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Kestra Medical Techs Price Target Maintained With a $32.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 09:58 AM UTC
H
KMTS: Q1 revenue up 60% YoY, gross margin expands, FY 2027 guidance raised to $141M
Revenue grew 60% YoY to $31M with gross margin up to 56.5%, driven by market expansion, higher in-network mix, and operational leverage. FY 2027 revenue guidance was raised to $141M (48% growth), with gross margin target
EARNINGS | Sep 14, 2026, 10:45 PM UTC
H
KMTS: Q1 revenue up 60% to $31M; FY27 guidance raised to $141M with gross margin target mid-70%
Revenue grew 60% year-over-year to $31M with gross margin expanding to 56.5%. FY27 guidance was raised to $141M (48% growth), driven by market expansion, share gains, and improved in-network mix. Gross margin target incr
EARNINGS | Sep 14, 2026, 09:54 PM UTC
H
Transcript: Kestra Medical Techs Q1 2027 Earnings Conference Call
Kestra Medical Techs (NASDAQ: KMTS ) released first-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and fina
LIVE | Sep 14, 2026, 09:45 PM UTC
L
KESTRA MEDICAL TECHNOLOGIES, LTD. 1Q 2027: Revenue $30.97M, EPS $(0.75) — 10-Q Summary
KESTRA MEDICAL TECHNOLOGIES, LTD. reported first-quarter 2027 results for the three months ended July 31, 2026, with revenue of $30.97M, up 60% year over year, and a net loss attributable to common shareholders of $(44.0
EARNINGS | Sep 14, 2026, 09:22 PM UTC
L
KMTS: Revenue up 60% and gross profit nearly doubled, but net loss widened on higher expenses
Revenue grew 60% year-over-year to $31.0 million, with gross profit nearly doubling and improved margins. Net loss widened to $44.1 million due to higher operating expenses and a $6.3 million debt extinguishment loss. Li
EARNINGS | Sep 14, 2026, 09:20 PM UTC
H
Kestra Medical Technologies, Ltd. reports results for the quarter ended April 30 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 14 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, cont
EARNINGS | Sep 14, 2026, 09:01 PM UTC
L
Kestra Medical Reports F1Q27 Revenue $31.0M; Gross Margin 56.5%
Kestra Medical reported first-quarter fiscal 2027 results for the period ended July 31, 2026, with revenue of $31.0 million and gross profit of $17.5 million. The company expanded gross margin to 56.5% and posted a GAAP
EARNINGS | Sep 14, 2026, 08:16 PM UTC
L
Kestra Medical Technologies Q1 revenue beats estimates, raises FY revenue outlook
OverviewOutlookResult DriversCompany press release:Key Details*Applies to a deviation of less than 1%; not applicable for per-share numbers.Analyst CoverageReuters Recommended ReadsFor questions concerning the data in th
EARNINGS | Sep 14, 2026, 08:12 PM UTC
H
KMTS: Revenue up 60% year-over-year, gross margin at 56.5%, FY27 guidance raised to $141M
Revenue surged 60% year-over-year to $31.0 million with gross margin expanding to 56.5%. Net loss widened to $44.1 million, while FY27 revenue guidance was raised to $141 million, reflecting 48% projected growth.Original
EARNINGS | Sep 14, 2026, 08:06 PM UTC
H
Kestra Medical Techs Prior FY27 Rev Guidance of $137 M >KMTS
Kestra Medical Techs Prior FY27 Rev Guidance of $137 M >KMTS
NEWS | Sep 14, 2026, 08:02 PM UTC
H
Kestra Medical Raised Guidance Represents Growth of 48% Compared to FY26 >KMTS
Kestra Medical Raised Guidance Represents Growth of 48% Compared to FY26 >KMTS
NEWS | Sep 14, 2026, 08:02 PM UTC
L
Kestra Medical Techs Raises FY27 View To Rev $141M >KMTS
Kestra Medical Techs Raises FY27 View To Rev $141M >KMTS
NEWS | Sep 14, 2026, 08:02 PM UTC
H
Kestra Medical Techs Raises FY2027 Sales Guidance from $137.000M to $141.000M vs $137.023M Est
Kestra Medical Techs (NASDAQ: KMTS ) raises FY2027 sales outlook from $137.000 million to $141.000 million vs $137.023 million estimate.
LIVE | Sep 14, 2026, 08:01 PM UTC
L
Kestra Medical Techs 1Q Rev $31M >KMTS
Kestra Medical Techs 1Q Rev $31M >KMTS
NEWS | Sep 14, 2026, 08:01 PM UTC
L
Kestra Medical Techs 1Q Loss/Shr 75c >KMTS
Kestra Medical Techs 1Q Loss/Shr 75c >KMTS
NEWS | Sep 14, 2026, 08:01 PM UTC
L
KMTS - Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
KMTS - Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
EARNINGS | Sep 14, 2026, 08:01 PM UTC
M
Kestra Medical Technologies Q1’26 results set for Sept. 14
Kestra Medical Technologies is scheduled to report Q1’26 results on September 14 after the market closes, with results expected to be disclosed at 4:00 PM ET.
EQUITY | Sep 11, 2026, 11:00 AM UTC
L
Kestra Medical names Daniel Finney vice president of research & development
Kestra Medical Technologies said Daniel Finney has been named Vice President of Research & Development and appointed to the company’s executive leadership team.
EQUITY | Sep 10, 2026, 10:01 AM UTC
L
KMTS - Kestra Names Daniel Finney Vice President of Research & Development
KMTS - Kestra Names Daniel Finney Vice President of Research & Development
GEOPOLITICS | Sep 10, 2026, 10:00 AM UTC
L
Director elections and auditor ratification passed at KMTS meeting
Shareholders approved director elections and auditor ratification; no questions were submitted during the Q&A session. Final voting results will be filed in a Form 8-K.
EQUITY | Sep 09, 2026, 01:56 PM UTC
L
Director elections and auditor ratification pass at KMTS meeting
The meeting approved all proposals, including director elections and auditor ratification. No shareholder questions were received during the Q&A session.
EQUITY | Sep 09, 2026, 01:51 PM UTC
L
BTIG maintains KMTS price target at $32.00 per share
Benzinga (via TradingView News) reports BTIG maintained its KMTS price target at $32.00 per share. The firm’s target was reiterated, not revised.
EQUITY | Sep 02, 2026, 10:20 AM UTC
L
KMTS to report first quarter fiscal 2027 results Sept. 14
Kestra Medical Technologies scheduled to report first quarter fiscal 2027 financial results on September 14.
EARNINGS | Aug 31, 2026, 08:08 PM UTC
L
KMTS to report first quarter fiscal 2027 results September 14
Kestra Medical Technologies (KMTS) will report first quarter fiscal 2027 financial results on September 14.
EARNINGS | Aug 31, 2026, 08:01 PM UTC
L
Kestra appoints Curtis Kopf as senior VP of customer experience
TradeXchange Newsdesk reports Kestra has appointed Curtis Kopf as Senior Vice President of Customer Experience.
EQUITY | Aug 26, 2026, 10:00 AM UTC
M
Analysts Initiate CSQR, GWRE, KMTS, STDN
Multiple analysts initiate coverage on several stocks
EQUITY | Aug 10, 2026, 10:51 AM UTC
L
Kestra Medical reports Q4 EPS (67c), consensus (58c)
Reports Q4 revenue...
EARNINGS | Jul 14, 2026, 08:06 PM UTC
H
Earnings Flash (KMTS) Kestra Medical Technologies, Ltd. Reports Q4 Revenue $28.6M, vs. FactSet Est of $26.5M
() -- Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.
EARNINGS | Jul 14, 2026, 08:01 PM UTC